![Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07701-8/MediaObjects/12885_2020_7701_Fig1_HTML.png)
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
![The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332220310052-gr5.jpg)
The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect
![Cytarabine (1-β-D-Arabinofuranosylcytosine, NSC 63878, NSC 287459, U-19920A, CAS Number: 147-94-4) | Cayman Chemical Cytarabine (1-β-D-Arabinofuranosylcytosine, NSC 63878, NSC 287459, U-19920A, CAS Number: 147-94-4) | Cayman Chemical](https://www.caymanchem.com/images/catalog/screen/16069.png)
Cytarabine (1-β-D-Arabinofuranosylcytosine, NSC 63878, NSC 287459, U-19920A, CAS Number: 147-94-4) | Cayman Chemical
![Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (AL Stock Vector Image & Art - Alamy Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (AL Stock Vector Image & Art - Alamy](https://c8.alamy.com/comp/KXYGR0/cytarabine-cytosine-arabinoside-ara-c-chemotherapy-drug-molecule-used-KXYGR0.jpg)
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (AL Stock Vector Image & Art - Alamy
![Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies | Leukemia Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies | Leukemia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fleu.2012.1/MediaObjects/41375_2012_Article_BFleu20121_Fig1_HTML.jpg)
Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies | Leukemia
![Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function - ScienceDirect Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0891584918307457-fx1.jpg)
Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function - ScienceDirect
![Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/a23f698c-59a5-4180-9cc7-94b5fb20e70b/emmm201910419-abs-0001-m.jpg)
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
![Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells | HTML Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells | HTML](https://www.mdpi.com/molecules/molecules-22-00499/article_deploy/html/images/molecules-22-00499-g001.png)
Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells | HTML
![Structural basis for polymerase η–promoted resistance to the anticancer nucleoside analog cytarabine | Scientific Reports Structural basis for polymerase η–promoted resistance to the anticancer nucleoside analog cytarabine | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-018-30796-w/MediaObjects/41598_2018_30796_Fig1_HTML.png)